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Purpose: Evaluate changes from baseline in health-related quality of life (QoL) in Japanese 
patients with episodic migraine receiving preventive treatment with galcanezumab (GMB).
Patients and Methods: Preventive treatments for migraine have been shown to improve 
QoL, but few clinical trials have examined QoL outcomes in Japanese patients. This phase 2, 
randomized, double-blind, placebo-controlled study was conducted at 40 centers in Japan. 
Patients aged 18–65 years with episodic migraine (4–14 monthly migraine headache days) 
received GMB 120 mg (n=115), 240 mg (n=114), or placebo (PBO, n=230) as monthly 
subcutaneous injections for 6 months. QoL was measured monthly using the Migraine- 
Specific Quality-of-Life Questionnaire (MSQ) version 2.1. Prespecified analyses were differ-
ences between GMB and PBO for change from baseline in all 3 domains of the MSQ and 
MSQ-Total, for each month and the average over Months 4–6.
Results: Treatment with GMB significantly increased MSQ scores from baseline vs PBO. 
Average change ± SE from baseline across Months 4–6 was 10.12±0.72 (PBO), 17.13±1.03 
(GMB 120 mg; P<0.001), and 15.91±1.03 (GMB 240 mg; P<0.001) for MSQ Role Function- 
Restrictive; 4.80±0.65 (PBO), 9.64±0.93 (GMB 120 mg; P<0.001), and 8.35±0.93 (GMB 240 mg; 
P<0.05) for MSQ Role Function-Preventive (MSQ-RFP); 3.46±0.77 (PBO), 10.04±1.10 
(GMB 120 mg; P<0.001), and 7.73±1.10 (GMB 240 mg; P<0.05) for MSQ Emotional Function, 
and 7.14±0.67 (PBO), 13.46±0.95 (GMB 120 mg; P<0.001), and 11.98±0.95 (GMB 240 mg; 
P<0.001) for MSQ-Total. Significantly greater improvement in scores in all MSQ domains and 
MSQ-Total was observed for both GMB doses vs PBO at Month 1 and was maintained for Months 
1–6 (excluding Month 5 for MSQ-RFP).
Conclusion: Preventive treatment with GMB 120 mg/240 mg improves MSQ scores in Japanese 
patients with episodic migraine. Improvements were seen within the first month and maintained for 
6 months and are similar to those seen in global studies enrolling primarily Caucasian patients.
Clinical Trial Registration: ClinicalTrials.gov, NCT02959177 (registered November 7, 
2016).
Keywords: MeSH: preventive therapy, quality of life
Introduction
Migraine is a chronic neurological disease that is estimated to affect approximately 
1 billion people worldwide and is a common cause of disability, particularly in 
young adult to middle-aged women.1 People with migraine experience significant 
functional and quality-of-life (QoL) impacts as a result of the disease, such as 
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reduced occupational functioning, reduced ability to per-
form household work, and limitations on family responsi-
bilities and social and leisure activities.2,3 In Japan, 
migraine affects 6.0–8.4% of the population.4,5 More 
than 25% of Japanese patients with migraine experience 
more than 3 headache days per month.5 For those who 
seek care from a healthcare provider, 34–38% of Japanese 
patients experience reductions in productivity in both paid 
and unpaid activities.6
Preventive treatment benefits many people with 
migraine, in terms of not only reduction in frequency of 
migraine attacks,7,8 but also QoL improvements.9–11 The 
identification of calcitonin gene-related peptide (CGRP) 
and its role in the pathophysiology of migraine has led to 
the development of preventive treatment comprising mono-
clonal antibodies such as galcanezumab (GMB), as well as 
small molecules. Galcanezumab is a humanized IgG4 mono-
clonal antibody that binds CGRP and prevents its biological 
activity without binding the CGRP receptor. Treatment with 
GMB has been shown to significantly reduce monthly 
migraine headache days12,13 and improve patient-reported 
QoL measures.14,15 To date, detailed QoL studies associated 
with GMB trials have focused on Caucasian populations.14,15 
It is currently unknown whether similar functional improve-
ments would be seen in Japanese populations.
The objective of this prespecified analysis was to eval-
uate changes from baseline in health-related QoL, mea-
sured via the Migraine-Specific Quality-of-Life 
Questionnaire (MSQ) version 2.1, using data from 
a randomized, double-blind, placebo (PBO)-controlled 
clinical trial in Japanese patients treated with GMB 
(120 mg or 240 mg) or PBO.16
Patients and Methods
Study Design
This was a phase 2, randomized, double-blind, PBO- 
controlled study of GMB in Japanese patients with episodic 
migraine. The study was conducted at 40 sites in Japan from 
December 2016 to January 2019. The protocol was approved 
by local independent ethics review boards. The study was 
conducted in accordance with the Declaration of Helsinki, 
the International Council for Harmonisation (Guideline for 
Good Clinical Practice), and applicable laws and regulations. 
All patients provided written informed consent before parti-
cipating in the study. The study was registered at www. 
clinicaltrials.gov (NCT02959177).
The study comprised 4 periods (Figure S1): a screening 
period, including full clinical assessment and washout of pre-
ventive treatments for migraine for ≥30 days; a baseline period 
to confirm patient eligibility and establish baseline number of 
migraine headache days using an electronic patient-reported 
outcome (ePRO) diary; a 6-month, double-blind treatment 
phase, in which patients completed the ePRO diary 
every day and QoL questionnaires using an electronic clinical 
outcome assessment tool every month; and a 4-month washout 
and follow-up phase. Patients who completed the treatment 
phase had the option to roll over to an open-label extension 
study (NCT02959190). Most patients (54%) moved to the 
extension study without completing the follow-up phase.
Study Population
Eligible patients were male or female, aged 18–65 years, 
with migraine with or without aura, had onset of migraine 
before age 50, and had the disease for at least 1 year 
before entering the study. Migraine frequency of eligible 
patients was 4–14 monthly migraine headache days with at 
least 2 attacks per month; monthly migraine headache days 
were defined as a calendar day on which a migraine head-
ache or probable migraine headache occurred. Patients 
were not eligible if they were currently taking preventive 
treatments for migraine (although they had the option to 
stop other preventive treatments and go through a washout 
period of ≥30 days), had a higher monthly frequency of 
headache days (≥15 monthly headache days during the 3 
months before the screening period), or had chronic 
migraine. Patients were also excluded if they had failed 
to respond to 3 or more adequately dosed preventive 
treatments for migraine from different classes. Additional 
reasons for exclusion are described in the primary analysis 
of the clinical trial.16
Treatment Protocol
Patients were randomized (2:1:1) to 1 of 3 treatment groups, 
receiving PBO, GMB 120 mg, or GMB 240 mg, respectively. 
Treatments were administered once monthly by subcuta-
neous injection. Patients randomized to GMB 120 mg 
received a loading dose of 240 mg at the first injection only 
(Month 0).
Health Outcome Measures
The impact of migraine on health-related QoL, a secondary 
objective of the clinical trial, was measured using the MSQ 
version 2.1 (distributed by Mapi Research Trust; https://epro 
vide.mapi-trust.org/instruments/migraine-specific-quality-of- 
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life-questionnaire).17 The MSQ version 2.1 is a 14-item ques-
tionnaire that measures QoL impacts in 3 domains: Role 
Function-Restrictive (RFR), 7 items that measure the func-
tional impact of migraine through limitations on daily social 
and work activities; Role Function-Preventive (RFP), 4 items 
that measure the impact of migraine through prevention of 
daily work and social activities; and Emotional Function (EF), 
3 items that assess the emotional impact of migraine.17,18 Raw 
scores in each domain were computed as a sum of relevant 
item scores, whereas the raw total score was the sum of all 
item scores; these were rescaled from 0–100, with a higher 
score indicating better QoL.18 The MSQ version 2.1 has 
demonstrated construct validity17 and is a psychometrically 
valid tool for reliable measurement of QoL impacts on patients 
with migraine.18 In particular, the RFR domain is a valuable 
tool for assessing the functional impact of migraine in chronic 
and episodic migraine clinical trials.19 The MSQ was admi-
nistered at baseline, monthly from Months 1–6, and at the end 
of the washout period (Month 10).
Statistical Analysis
Mean changes from baseline to each visit for total MSQ 
score (MSQ-Total) and individual domain scores were 
assessed using a restricted maximum likelihood–based 
mixed-model repeated measures (MMRM) technique 
and are reported as least squares (LS) means ± standard 
error (SE). The prespecified MMRM analysis included 
fixed categorical effects (treatment, month, treatment-by- 
month interaction, and baseline monthly migraine head-
ache days category [<8, ≥8]) and continuous fixed cov-
ariates (baseline value and baseline-by-month 
interaction). No adjustments for multiplicity were made 
across the arms, time points, and analyses described in 
this article. Significance was based on a 2-sided alpha 
level of 0.05. The prespecified endpoint for comparison 
of GMB with PBO was estimated as the average across 
Months 4–6 (LS means) using PROC MIXED. This end-
point was selected because it was hypothesized that QoL 
improvements might not be apparent until after patients 
experienced a significant reduction in monthly migraine 
headache days, which would be more likely in the latter 
half of the study period. MSQ-RFR domain responders 
were defined as patients whose average change from 
baseline was ≥25 over Months 4–6; a change of ≥25 is 
equivalent to 9 points on the raw scale and is an appro-
priate threshold to interpret a benefit from treatment.19 
These data were analyzed using a logistic regression 
model, which included treatment, baseline, and baseline 
monthly migraine headache days category (<8, ≥8).20 
A post hoc MMRM analysis of the change from baseline 
in MSQ scores by baseline monthly migraine headache 
days (subgroups: <8 days/month vs ≥8 days/month) was 
performed for each group separately. This analysis 
included fixed categorical effects (treatment, month, and 
treatment-by-month interaction) and continuous fixed 
covariates (baseline value and baseline-by-month interac-
tion). All statistical analyses were performed using SAS® 
version 9.4 (SAS Institute, Cary, NC, USA). All authors 
had access to the data during the preparation of the 
manuscript.
Results
Demographic and Baseline Clinical 
Characteristics
Patient demographics have been previously reported.16 
Briefly, patient demographics and clinical characteristics 
were similar across all treatment groups, with the majority of 
patients being female (83.4%) and an average age of 44 years. 
Approximately 80% of patients were engaged in paid employ-
ment. Patients had a mean duration of migraine of >20 years 
and experienced 8.6–9.0 monthly migraine headache days. 
Baseline Migraine Disability Assessment (MIDAS) scores 
ranged from 13.7–15.8 (MIDAS Grade III). Baseline MSQ 
scores were not significantly different across the treatment 
groups (Table 1).
QoL Outcomes
Functional Outcome (MSQ-RFR Domain)
Treatment with GMB significantly increased MSQ-RFR 
scores from baseline compared with PBO, indicating an 
improvement in patient functioning (Figure 1). As pre-
viously reported, the mean change ± SE from baseline 
over Months 4–6 in MSQ-RFR was 17.13±1.03 for GMB 
120 mg and 15.91±1.03 for GMB 240 mg, compared with 
only 10.12±0.72 for PBO (P<0.001 GMB vs PBO).16 The 
Table 1 MSQ Scores at Baseline
PBO GMB 120 mg GMB 240 mg
MSQ-RFR 68.1 (14.5) 66.2 (17.0) 67.6 (13.7)
MSQ-RFP 81.9 (13.7) 82.6 (15.8) 83.5 (12.2)
MSQ-EF 79.8 (17.6) 78.6 (22.5) 82.4 (14.9)
MSQ-Total 74.6 (13.5) 73.5 (16.7) 75.3 (12.0)
Note: Data are mean (SD). 
Abbreviations: EF, Emotional Function domain; GMB, galcanezumab; MSQ, 
Migraine-Specific Quality-of-Life Questionnaire; PBO, placebo; RFP, Role Function- 
Preventive domain; RFR, Role Function-Restrictive domain; SD, standard deviation.
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current analyses demonstrate that the effects of GMB treat-
ment on patient functioning were observed within the first 
month. The change from baseline in MSQ-RFR scores was 
significantly higher for both doses of GMB than PBO at 
Month 1 and was maintained through Month 6 (Figure 1; 
P<0.05 GMB vs PBO at each month). At the end of the 
4-month washout and follow-up phase (Month 10), the 
significant differences between GMB-treated groups and 
PBO had disappeared; however, MSQ-RFR had not 
returned to baseline levels (Figure 1). Change from baseline 
in MSQ-RFR was not affected by baseline monthly 
migraine headache day frequency (Table S1).
MSQ-RFR domain responders were defined as those 
with an average change in RFR scores from baseline ≥25 
for Months 4–6. GMB-treated patients had a higher respon-
der rate than patients receiving PBO (Table 2; P=0.008 
GMB 120 mg vs PBO, P<0.001 GMB 240 mg vs PBO).
Preventive and Emotional Outcomes (MSQ-RFP and 
MSQ-EF)
Other QoL measurements were also improved by GMB 
treatment. Patients receiving GMB showed significant 
increases from baseline in the other MSQ domain scores 
compared with PBO (Figure 2). Although changes from 
baseline in MSQ scores in the RFP and EF domains were 
smaller than those in RFR, they were statistically sig-
nificant (P<0.001 vs baseline). In the RFP domain, the 
average change from the baseline score over Months 4–6 
was 9.6 for GMB 120 mg and 8.4 for GMB 240 mg vs 
4.8 for PBO (Figure 2A; P<0.05 GMB vs PBO). In the 
EF domain, the average increase from baseline over 
Months 4–6 was 10.0 and 7.7 for GMB 120 mg and 
240 mg, respectively, compared with 3.5 for PBO 
(Figure 2B; P<0.05 GMB vs PBO). The changes from 
baseline in RFP and EF scores were significantly higher 
(P<0.05) for the GMB groups vs PBO in each month 
from Month 1 through Month 6 (Figure 2D and 2E), 
with the exception of Month 5 for MSQ-RFP scores 
(Figure 2D). At Month 10, both RFP and EF domain 
scores remained above baseline levels for all treatment 
groups (Figure 2D and 2E). The change from baseline at 
Month 10 in MSQ-EF was significantly higher for GMB 
120 mg vs PBO (P<0.05; Figure 2E), but there was no 
difference between GMB-treated groups and PBO at 
Month 10 in the RFP domain (Figure 2D). Changes 
from baseline in MSQ-RFP and MSQ-EF were not 
affected by baseline monthly migraine headache day fre-
quency (Table S1).
Overall QoL Outcome (MSQ-Total)
Overall, treatment with GMB resulted in improved QoL com-
pared with PBO, as measured by changes in MSQ-Total. The 
increase from baseline in MSQ-Total was significantly higher 
for both doses of GMB vs PBO (Figure 2C and 2F; P<0.05). 
MSQ-Total scores increased over Months 4–6 by an average 
of 13.5 and 12.0 for the GMB 120 mg and GMB 240 mg 
groups, respectively, compared with 7.1 for the PBO group 
(Figure 2C; P<0.001 GMB vs PBO). The change from base-
line in MSQ-Total scores was significantly higher (P<0.05) for 
the GMB groups vs PBO in each month from Month 1 through 
Figure 1 Monthly LS mean change in MSQ-RFR scores from baseline. Washout period 
denoted by gray shading. Patients had the option of entering an open-label extension 
period after Month 6. Number of patients at Month 10 reflects this option: n=98 for 
PBO, n=51 for GMB 120 mg, and n=51 for GMB 240 mg. *P<0.05 vs PBO (MMRM 
analysis). The average LS mean change from baseline over Months 4–6 in MSQ-RFR was 
10.12±0.72 for PBO, 7.13±1.03 for GMB 120 mg, and 15.91±1.03 for GMB 240 mg.16 
The MMRM model included the fixed categorical effects of treatment, month, and 
treatment-by-month interaction, the baseline number of monthly migraine headache 
days (<8, ≥8), and the continuous fixed covariates of baseline value and baseline-by- 
month interaction. 
Abbreviations: GMB, galcanezumab; LS, least squares; MMRM, mixed-model 
repeated measures; MSQ-RFR, Migraine-Specific Quality-of-Life Questionnaire 
Role Function-Restrictive domain; PBO, placebo; SE, standard error.
Table 2 MSQ-RFR Responders by Treatment Group





PBO 228 11.8 - -
GMB 120 mg 112 25.0 2.86 (1.33–6.17) 0.008
GMB 240 mg 112 25.9 3.91 (1.89–8.10) <0.001
Notes: an = number of intent-to-treat subjects who have non-missing baseline values and 
≥1 post-baseline value at Month 4, 5, or 6; bVs PBO; cP-values from logistic regression: 
responder indicator = treatment, baseline, and baseline number of monthly migraine 
headache days (<8, ≥8). Responders were defined as patients whose change from 
baseline to average of Months 4–6 in the MSQ-RFR domain was ≥25. 
Abbreviations: CI, confidence interval; GMB, galcanezumab; MSQ-RFR, Migraine- 
Specific Quality-of-Life Questionnaire Role Function-Restrictive domain; PBO, 
placebo.
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Month 6 (Figure 2F). There were no differences between 
GMB-treated groups and PBO at Month 10, although MSQ- 
Total in GMB-treated groups had not returned to baseline 
levels (Figure 2F). Change from baseline in MSQ-Total was 
not affected by baseline monthly migraine headache day fre-
quency (Table S1).
Discussion
This is the first randomized controlled trial in Japanese 
patients with migraine receiving preventive treatment with 
GMB (120 mg or 240 mg) that demonstrates improve-
ments from baseline in QoL measures (MSQ scores) com-
pared with PBO. Improvement within 1 month after 
initiating treatment was observed across all MSQ domains 
and individual questions; this is clinically relevant as 
improved function in daily life is essential for patients 
with migraine. The findings of this study are consistent 
with those seen in Caucasian, Hispanic, and East Asian 
populations and support the consistency of benefit of GMB 
across different ethnic populations.
Evaluation of the consistency of efficacy, safety, and 
overall patient experience of new medications across dif-
ferent ethnic populations is important from both 
a scientific and a regulatory perspective. In the current 
study, the pattern of increased scores for MSQ-Total and 
all MSQ domains with GMB treatment in Japanese 
patients parallels the results seen in the large global 
EVOLVE-1 and EVOLVE-2 Phase 3 clinical trials.15 
However, the observed changes from baseline in the cur-
rent study were smaller than those seen in the global 
clinical trials. This can be explained in part by the 
Japanese population having higher baseline MSQ scores 
than the patients in either EVOLVE-1 or EVOLVE-2 (up 
to 25 points higher).15 A previous study in Japanese 
patients found that mean MSQ domain scores were 
15–20 points higher than those of patients from the 
United States,21 and it has been suggested that the higher 
MSQ scores may reflect cultural differences around per-
ception and coping with pain and discomfort.16 Despite 
this, the observed changes from baseline in the present 
study were significantly different from PBO in all 3 
domains of the MSQ; these QoL findings are consistent 
with the efficacy and safety data for GMB in Japanese 
patients with episodic migraine.16 Notably, the current 
analyses showed higher odds ratios for MSQ-RFR respon-
ders compared with those seen in previous studies of 
GMB. For episodic migraine, an MSQ-RFR responder is 
a patient whose RFR score increases by ≥25 from baseline 
Figure 2 LS mean changes from baseline in additional MSQ scores. Bar graphs: average LS mean change from baseline over Months 4–6 in (A) MSQ-RFP, (B) MSQ-EF, and 
(C) MSQ-Total scores. Line graphs: monthly LS mean changes from baseline in (D) MSQ-RFP, (E) MSQ-EF, and (F) MSQ-Total scores. Washout period denoted by gray 
shading. Patients had the option of entering an open-label extension period after Month 6. Number of patients at Month 10 reflects this option: n=98 for PBO, n=51 for 
GMB 120 mg, and n=51 for GMB 240 mg. *P<0.05 vs PBO (MMRM analysis). The MMRM model included the fixed categorical effects of treatment, month, and treatment-by- 
month interaction, the baseline number of monthly migraine headache days (<8, ≥8), and the continuous fixed covariates of baseline value and baseline-by-month interaction. 
Abbreviations: EF, Emotional Function domain; GMB, galcanezumab; LS, least squares; MMRM, mixed-model repeated measures; MSQ, Migraine-Specific Quality-of-Life 
Questionnaire; PBO, placebo; RFP, Role Function-Preventive domain; SE, standard error.
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to Months 4–6 on average.19 In the current study, GMB- 
treated patients had a higher MSQ-RFR responder rate 
than patients receiving PBO (odds ratio 2.86 [95% CI: 
1.33–6.17] and 3.91 [1.89–8.10] for GMB 120 mg and 
240 mg, respectively). In the EVOLVE-1, EVOLVE-2, 
and REGAIN trials, MSQ-RFR responder odds ratios 
were 1.64–2.27 for patients receiving GMB 120 mg and 
1.66–2.45 for those receiving GMB 240 mg.19 It appears 
that, despite on average starting from a higher MSQ-RFR 
baseline than Caucasian populations, more Japanese 
patients are able to achieve clinically significant improve-
ments in this QoL domain when receiving GMB treatment 
compared with PBO. In addition to the EVOLVE-1 and 
EVOLVE-2 trials noted above, other clinical trials of 
GMB that assessed MSQ measures are not as directly 
comparable because of differences in trial durations and 
migraine diagnoses (chronic or episodic). However, these 
studies, conducted in the United States, Europe, and 
Central and South America, also show lower baseline 
scores and greater increases from baseline than in the 
present study.14,22,23
Insufficient efficacy of preventive medications can 
impact patient adherence and persistence with 
treatment.24 For Japanese patients with episodic migraine 
or chronic migraine who have experienced problems with 
medication, lack of efficacy was the most common issue.6 
In the present study, improvements in MSQ scores were 
seen within 1 month of treatment with GMB. Mean 
monthly migraine headache days were also reduced within 
1 month of GMB treatment.16 In a clinical setting, these 
early improvements in symptoms and health-related QoL 
might be expected to contribute to adherence and persis-
tence with GMB treatment. This supposition is supported 
by the high compliance rate (100%) and continuation rate 
(95.9%)16 in the present study.
In the current study, MSQ was measured again 4 months 
after GMB treatment ceased. Although post-treatment MSQ 
scores decreased somewhat, they remained above baseline 
levels. However, no differences in most MSQ domains were 
observed between GMB-treated groups and PBO 4 months 
after ceasing GMB. The maintenance in the treatment gains 
observed with GMB on MSQ scores is clinically important, 
as it suggests that withdrawal of GMB is unlikely to lead to 
an immediate worsening in patient health-related QoL.
Positive effects on QoL outcomes have been reported 
in global trials for other CGRP monoclonal antibodies 
such as erenumab, eptinezumab, and fremanezumab.25–29 
However, because of the differences in the time point 
evaluation, trial design, and patient-reported outcomes 
used, it is difficult to make direct comparisons between 
studies. Furthermore, these trials focused primarily on 
Caucasian populations and not on Japanese people with 
migraine. Similarly, although preventive medications 
such as antiepileptic drugs, beta-blockers, triptans, and 
antidepressants have demonstrated improvements in QoL 
in global trials, most studies have not used migraine- 
specific QoL instruments such as the MSQ.9,30 Two 
notable exceptions are onabotulinumtoxinA and topira-
mate, neither of which has received regulatory approval 
for the prevention of migraine in Japan. Both these 
medications have demonstrated statistically significant 
improvements in the MSQ. Depending on the study, 
these improvements were seen in all 3 domains or in 
the RFR and RFP domains only.10,11,30
The strengths of the present study include its rando-
mized, controlled, double-blind design and the fact that its 
6-month duration of treatment enabled more accurate mea-
surement of changes in functioning over time. 
Additionally, the patient-reported outcome measure used 
(MSQ) is a migraine-specific tool and, unlike more general 
QoL scales, assesses aspects of daily life that are important 
to patients with migraine. Another strength of this study is 
the focus on Japanese patients, who have previously been 
understudied with regard to CGRP antibody therapies.
There are limitations to this research. The results reported 
were not the primary objective of the clinical trial, and no 
adjustments for multiplicity were performed. It is unclear 
whether these results can be extrapolated to patients with 
lower-frequency episodic migraine (all study participants 
had a monthly migraine headache frequency of 4–14 headache 
days per month). GMB treatment was examined as 
a monotherapy (although acute medications were allowed 
under certain circumstances). QoL outcomes for concurrent 
usage of GMB with other preventive medications are currently 
unknown.
Conclusion
This is the first study to demonstrate that both 120-mg and 
240-mg doses of GMB were superior to PBO in improving 
patient functioning as measured by the MSQ version 2.1. 
This benefit in Japanese patients with episodic migraine 
was observed within the first month of treatment and was 
maintained for 6 months. The improvements in function-
ing observed in Japanese patients with migraine were 
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consistent with findings from global studies, which have 
primarily examined Caucasian populations.
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